These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23500327)

  • 1. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
    Erickson KF; Japa S; Owens DK; Chertow GM; Garber AM; Goldhaber-Fiebert JD
    J Am Coll Cardiol; 2013 Mar; 61(12):1250-8. PubMed ID: 23500327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular disease: The price of a QALY--cost-effectiveness of statins in CKD.
    Jha V; Modi GK
    Nat Rev Nephrol; 2013 Jul; 9(7):377-9. PubMed ID: 23732458
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.
    McConnachie A; Walker A; Robertson M; Marchbank L; Peacock J; Packard CJ; Cobbe SM; Ford I
    Eur Heart J; 2014 Feb; 35(5):290-8. PubMed ID: 23839541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States.
    Boettiger DC; Newall AT; Phillips A; Bendavid E; Law MG; Ryom L; Reiss P; Mocroft A; Bonnet F; Weber R; El-Sadr W; d'Arminio Monforte A; de Wit S; Pradier C; Hatleberg CI; Lundgren J; Sabin C; Kahn JG; Kazi DS
    J Int AIDS Soc; 2021 Mar; 24(3):e25690. PubMed ID: 33749164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
    Boettiger DC; Newall AT; Chattranukulchai P; Chaiwarith R; Khusuwan S; Avihingsanon A; Phillips A; Bendavid E; Law MG; Kahn JG; Ross J; Bautista-Arredondo S; Kiertiburanakul S
    J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25494. PubMed ID: 32562359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP; Visseren FL; de Wit GA; Algra A
    BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
    Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
    Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.
    Ganz DA; Kuntz KM; Jacobson GA; Avorn J
    Ann Intern Med; 2000 May; 132(10):780-7. PubMed ID: 10819700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study.
    Mihaylova B; Wu R; Zhou J; Williams C; Schlackow I; Emberson J; Reith C; Keech A; Robson J; Parnell R; Armitage J; Gray A; Simes J; Baigent C
    Heart; 2024 Oct; 110(21):1277-1285. PubMed ID: 39256053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States.
    Odden MC; Pletcher MJ; Coxson PG; Thekkethala D; Guzman D; Heller D; Goldman L; Bibbins-Domingo K
    Ann Intern Med; 2015 Apr; 162(8):533-41. PubMed ID: 25894023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease.
    Wang M; Liu J; Bellows BK; Qi Y; Sun J; Liu J; Moran AE; Zhao D
    Glob Heart; 2020 Jun; 15(1):43. PubMed ID: 32923337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
    Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
    Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk.
    Conly J; Clement F; Tonelli M; Hemmelgarn B; Klarenbach S; Lloyd A; McAlister FA; Husereau D; Wiebe N; Au F; Manns B;
    CMAJ; 2011 Nov; 183(16):E1180-8. PubMed ID: 21989469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.
    Pouwels XGLV; van Mil D; Kieneker LM; Boersma C; van Etten RW; Evers-Roeten B; Heerspink HJL; Hemmelder MH; Langelaan MLP; Thelen MHM; Gansevoort RT; Koffijberg H
    EClinicalMedicine; 2024 Feb; 68():102414. PubMed ID: 38299045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.